A practical reference on Stability data: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-08 and is reviewed periodically as new material appears.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Regulatory frameworks treat peptide purity as part of product quality, though requirements vary by intended use and jurisdiction. Investigational materials may need identity, strength, quality, and purity documentation. Compendial monographs, when available, specify tests and acceptance criteria for certain peptides. For research peptides, oversight is often less prescriptive, and buyers may rely on supplier documentation. Open questions remain about how to standardize impurity reporting across laboratories and how to define purity for complex or modified peptides.
Quality control for peptide products relies on written procedures, batch records, and certificates of analysis. A certificate of analysis typically lists the test methods, specifications, and results for a specific lot. Batch records document synthesis, purification, and testing steps so that results can be traced to process conditions. Method validation establishes accuracy, precision, specificity, linearity, and limits of detection. These records support consistency across lots and allow laboratories to investigate deviations when a specification is not met.
Storage conditions influence purity and therefore testing outcomes. Lyophilized peptides are generally kept cool and dry, while solutions may require refrigeration or freezing depending on sequence and buffer. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis. Testing after storage should use the same validated method as release testing to allow comparison. Stability studies examine how purity changes over time under defined temperature and humidity conditions. Results are compared against baseline data collected at release.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | RP-HPLC with UV detection | Separates by hydrophobicity; purity is method-dependent |
| Confirmatory method | LC-MS or MALDI-TOF MS | Provides molecular mass and impurity mass information |
| Common detection wavelength | 214 nm or 220 nm | Peptide bond absorbance; also 280 nm for aromatic residues |
| Typical purity specification | 95% or greater by HPLC area | Common research grade; exact threshold depends on application |
| Sample preparation | Dissolve in water/acetonitrile with acid | Formic acid or trifluoroacetic acid often used |
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Cervical drug delivery is a route of carrying drugs into the body through the vagina and cervix. This is a form of localized drug delivery that prevents the drugs from impacting unintended areas of the body, which can lower side effects of toxic drugs such as chemotherapeutics. Cervical drug delivery has specific applications for a variety of female health issues: treatment of cervical cancer, pregnancy prevention, STD prevention, and STD treatment.
In the most common means for its production, cells make 5-oxo-ETE in a four step pathway that involves their stimulus-induced activation of the following pathway: a) the release of arachidonic acid (i.e. 5Z,8Z,11Z,14Z-eicosatetraenoic acid) from its storage sites in membrane phospholipids due to the activation of phospholipase A2 enzymes; b) oxygenation of this arachidonic acid by activated arachidonate 5-lipoxygenase (ALOX5) to form 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HpETE); c) reduction of this 5(S)-HpETE by ubiquitous cellular peroxidases to form 5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HETE); and (d) the oxidation of 5(S)-HETE by a microsome-bound nicotinamide adenine dinucleotide phosphate (NADP+)-dependent dehydrogenase enzyme viz., 5-hydroxyeicosanoid dehydrogenase (5-HEDH), to form 5-oxo-ETE:
Developing standards-based messaging, to allow for automated data exchange Creating an exchange network, to ensure specific laboratories receive the information most pertinent to their work Improving reporting capabilities Selection and implementation of the best information management system for the laboratory's needs Strengthening the information network by sharing technical resources across public health laboratories One effort by the Informatics program is PHLIP, the Public Health Laboratory Interoperability Project. PHLIP aims to establish reliable laboratory data exchange between state public health laboratories and the CDC by fostering collaboration in IT and laboratory science.
AS9100 Revision C (2009), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision B to C is largely to address the following question: "Our supplier is repeatedly late on delivery and failing to meet our requirements, how is it possible that they still have their AS9100 certificate?" That is, the AS9100C changes are driven by repeated delivery of non-conforming product and repeated late delivery by organizations that held AS9100A/B certifications. Those organizations had documented controls that conformed to the standard, however, there were insufficient processes in place to assure effectiveness of those controls. The response in this AS9100 revision is to elevate the requirements for Risk Management and to make Risk Management an integrated theme throughout the standard. A major challenge to AS9100B-compliant organizations was the new AS9100 auditing standards defined in AS9101 Revision D, which eliminates the clause-based compliance checklist and requires organizations to provide evidence of effectiveness of their systems and processes. Summary of changes between AS9100B and AS9100C:
Different isoforms of actin are present in the cell nucleus. The level of actin isoforms may change in response to stimulation of cell growth or arrest of proliferation and transcriptional activity. Research on nuclear actin is focused on isoform beta. However the use of antibodies directed against different actin isoforms allows identifying not only the cytoplasmic beta in the cell nucleus, but also alpha- and gamma-actin in certain cell types. The presence of different isoforms of actin may have a significant effect on its function in nuclear processes, as the level of individual isoforms can be controlled independently. Functions of actin in the nucleus are associated with its ability to polymerize and interact with various ABPs and with structural elements of the nucleus. Nuclear actin is involved in:
Sources: en.wikipedia.org
ACTA2 (actin alpha 2) is an actin protein with several aliases including alpha-actin, alpha-actin-2, aortic smooth muscle or alpha smooth muscle actin (α-SMA, SMactin, alpha-SM-actin, ASMA). Actins are a family of globular multi-functional proteins that form microfilaments. ACTA2 is one of six different actin isoforms and is involved in the contractile apparatus of smooth muscle. ACTA2 (as with all the actins) is extremely highly conserved and found in nearly all mammals. In humans, ACTA2 is encoded by the ACTA2 gene located on 10q22-q24. Mutations in this gene cause a variety of vascular diseases, such as thoracic aortic disease, coronary artery disease, stroke, Moyamoya disease, and multisystemic smooth muscle dysfunction syndrome. ACTA2 (commonly referred to as alpha-smooth muscle actin or α-SMA) is often used as a marker of myofibroblast formation. Studies have shown that ACTA2 is associated with TGF-β pathway that enhances contractile properties of hepatic stellate cells leading to liver fibrosis and cirrhosis.
Alfred Ellis Wilhelmi (1910–1994) was an American endocrinologist recognized for contributing to the understanding of anterior pituitary hormones. Born in Lakewood, Ohio, Wilhelmi attended Cleveland public schools. Wilhelmi earned a B.S. degree in premedical sciences from Western Reserve University in 1933. He then attended Oxford University as a Rhodes Scholar, where he obtained a B.A. in 1933 and Ph.D. in animal physiology in 1937. He then joined Yale University's Biochemistry Department, rising to the position of Professor in 1950. Wilhelmi chaired the Department of Biochemistry at Emory University School of Medicine from 1950 to 1977. In 1960, he was named Charles Howard Candler Professor of Biochemistry. In 1979, he received Emory's Thomas Jefferson award for service to the university and community. Wilhelmi also was President of the Endocrine Society from 1968 to 1969. During his career, he published over 80 articles in scientific journals.
GPCRs become desensitized when exposed to their ligand for a long period of time. There are two recognized forms of desensitization: 1) homologous desensitization, in which the activated GPCR is downregulated; and 2) heterologous desensitization, wherein the activated GPCR causes downregulation of a different GPCR. The key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases. Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the receptor) via adenylate cyclase and cyclic AMP (cAMP). In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active the more kinases are activated and the more receptors are phosphorylated. In β2-adrenoceptors, this phosphorylation results in the switching of the coupling from the Gs class of G-protein to the Gi class. cAMP-dependent PKA mediated phosphorylation can cause heterologous desensitisation in receptors other than those activated.
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2023, it was the 244th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
Network Science, Part 5: Solvent-Accessible Surfaces AREAIMOL is a command line tool in the CCP4 Program Suite for calculating ASA. NACCESS solvent accessible area calculations. FreeSASA Open source command line tool, C library and Python module for calculating ASA. Surface Racer Oleg Tsodikov's Surface Racer program. Solvent accessible and molecular surface area and average curvature calculation. Free for academic use. ASA.py — a Python-based implementation of the Shrake-Rupley algorithm. Michel Sanner's Molecular Surface – the fastest program to calculate the excluded surface. pov4grasp render molecular surfaces. Molecular Surface Package — Michael Connolly's program. Volume Voxelator — A web-based tool to generate excluded surfaces. ASV freeware Analytical calculation of the volume and surface of the union of n spheres (Monte-Carlo calculation also provided). Vorlume Computing Surface Area and Volume of a Family of 3D Balls. GetArea Calculate solvent accessible surface area of proteins online. ProMS ProMS - Protein Molecular Surface Calculator
Sources: en.wikipedia.org
It usually refers to the relative area of the main peak in a chromatographic separation, such as RP-HPLC. It estimates the proportion of UV-absorbing material in that peak, not the absolute mass fraction of the target peptide. Different methods can give different percentages.
HPLC separates and quantifies components, while mass spectrometry identifies molecular masses. Together they can show whether a main peak has the expected mass and whether other peaks correspond to related peptide variants. This combination is more informative than either method alone.
Higher purity reduces the proportion of detectable related impurities, which can matter for research reproducibility. However, purity value alone does not establish identity, biological activity, or safety. The appropriate purity depends on the intended use and the sensitivity of the assay.
A certificate of analysis generally states the peptide identity, lot number, test methods, specifications, and measured results. It may also list storage recommendations, retest dates, and the name of the testing laboratory.